Request for report on The Use of Toxicogenomics in the Pharmaceutical and Biotechnology Industries

Thank you for your interest in receiving The Use of Toxicogenomics in the Pharmaceutical and Biotechnology Industries, based on a survey of 300 scientists in more than 90 companies and non-profit organizations. After you've taken a minute to answer the questions below, click submit, and we'll send you copy of the report.

Name
Job Title
Organization
Nature of Organization
(check one)		 pharm biotech academic government
Mailing address line 1
Mailing address line 2
City
State
Zip
E-mail address
Phone

1. What best describes your position? (check one)

Molecular toxicologist Safety pharmacologist Classical toxicologist
Pathologist Biologist/molecular biologist Bioinformatics specialist
Chemist Other

2. Is your company developing small molecule drugs?

Yes No

3. Is your company developing biologics?

Yes No

4. Is your organization currently using gene expression microarray technology in the preclinical evaluation of chemical compound or biologic safety (toxicogenomics)?

Yes No

5. Is your organization currently using gene expression microarray technology in the preclinical evaluation of chemical compound mechanisms of action (chemogenomics)?

Yes No

6. If your answer to either of the previous two questions was yes, how many compounds per year are you analyzing using the gene expression microarray technology?

1-3 3-5 5-10 >10 N/A

7. If you are not currently using toxico- or chemogenomics do you intend to use these approaches for evaluating either compound safety or compound mechanism of action within the next:

3 months 6 months 1 year >1 year No plans

8. What do you see as the primary objectives for using chemo- and toxicogenomics? (please rate each response)

Prioritize lead compounds
Screen for potential toxicities across a series of compounds
Understand the mechanism of toxicity for compounds with potential problems
Understand mechanisms of action of compounds
Support other safety assessments of compounds
Identify markers to predict toxicity
Identify markers to predict unanticipated pharmacological activity and side effects
Screen compounds during lead optimization to determine the lead series with the lowest probability of exhibiting safety problems
Other:

9. What are the greatest obstacles to applying toxicogenomics? (please rate each response)

Cost of microarrays
Microarray data analysis
Toxicogenomics does not provides sufficient value
Too difficult to incorporate toxicogenomics into current processes and procedures
Uncertainty what FDA will do with this new type of data
Requires more compound material than is available
Results are not timely enough to be useful

10. Where do you believe that toxico- or chemogenomics will be most valuable in drug discovery and preclinical development (within your organization)? (please rate each response)

In the evaluation of:
Leads in early lead optimization
Leads in late lead optimization
Drug candidates that are about to enter preclinical studies
Drug candidates or backup candidates where safety issues have already been identified in pre-clinical studies
Drug candidates or backup candidates where safety issues have already been identified in development
Other:

11. Would you also like to receive a copy of the Rat Liver Histopathology Atlas?

Yes No